Tickers

1. Composite Trajectory Verdict

For a pre-revenue, development-stage medical device company, the cash flow statement and balance sheet carry the most weight because they determine the entity's ability to continue operating and fund its path to potential revenue generation.

Composite Trajectory: Deteriorating

The annual cash burn from operations increased 48% year-over-year to $12.3 million (10-K FY2026, Consolidated Statements of Cash Flows), while the cash balance fell from $9.1 million to $7.0 million (10-K FY2026, Consolidated Balance Sheets). The June 30, 2026 quarterly filing shows cash further declining to $3.5 million with operating cash burn of $3.5 million in a single quarter (10-Q Q1 FY2027, Condensed Statements of Cash Flows). Working capital contracted from $7.9 million to $5.9 million to $3.1 million across the three reporting dates (10-K FY2025, 10-K FY2026, 10-Q Q1 FY2027). The accumulated deficit grew from $50.4 million to $67.1 million to $69.8 million (same sources). Although the most recent quarter showed a lower net loss than the year-ago quarter ($2.7 million vs $3.3 million), the cash burn in that quarter was higher ($3.5 million vs $2.6 million) and no financing proceeds were received, accelerating the liquidity decline.

2. Red Flags

• Going concern doubt explicitly stated: "raises substantial doubt about our ability to continue as a going concern" with cash estimated to last only into Q4 2026 (10-K FY2026, MD&A) and later revised to Q1 2027 including subsequent financing (10-Q Q1 FY2027, Liquidity and Going Concern).
• Accelerating cash burn: Operating cash used increased from $8.3 million (FY2025) to $12.3 million (FY2026) to a $3.5 million quarterly run-rate in Q1 FY2027 (10-K FY2026, Consolidated Statements of Cash Flows; 10-Q Q1 FY2027, Condensed Statements of Cash Flows).
• Cash balance declining rapidly: $9.1 million (Mar 2025) → $7.0 million (Mar 2026) → $3.5 million (Jun 2026) (10-K FY2025, 10-K FY2026, 10-Q Q1 FY2027, Consolidated Balance Sheets).
• No revenue generation: Zero revenue reported across all periods (10-K FY2026, Statements of Operations; 10-Q Q3 FY2026, Consolidated Statements of Operations; 10-Q Q1 FY2027, Condensed Statements of Operations).
• Large warrant overhang: 10.8 million potentially dilutive securities outstanding as of March 31, 2026 (10-K FY2026, Note 3 – Equity), against only 11.4 million shares then outstanding.
• Stock option cancellation expense: $3.7 million of accelerated stock-based compensation recognized in FY2026 from cancellation agreements (10-K FY2026, Note 3 – Equity).
• Nasdaq bid price deficiency: Received deficiency notice Jan 14, 2026 for trading below $1.00; regained compliance July 9, 2026 (10-K FY2026, Note 1; 10-Q Q1 FY2027, Recent Developments).
• Financing dependency: All historical funding from equity/debt sales; $25-32 million additional capital estimated needed to commercialization (10-K FY2026, Liquidity and Capital Resources).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual results show clear deterioration: FY2026 net loss of $16.7 million vs $11.4 million in FY2025, a 47% increase, with total operating expenses rising 47% to $17.0 million (10-K FY2026, Consolidated Statements of Operations). R&D grew 51% to $7.1 million and G&A grew 44% to $9.9 million (same source). However, the most recent quarter (Q1 FY2027) shows improvement versus the year-ago quarter: net loss narrowed to $2.7 million from $3.3 million, and total operating expenses fell 19% to $2.8 million (10-Q Q1 FY2027, Condensed Statements of Operations). The intervening Q3 FY2026 showed deterioration versus Q3 FY2025: net loss widened to $3.3 million from $2.7 million and operating expenses rose 22% (10-Q Q3 FY2026, Consolidated Statements of Operations). The nine-month FY2026 loss of $14.0 million versus $8.2 million in the prior year (+71%) aligns with the annual trend (10-Q Q3 FY2026, Consolidated Statements of Operations).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Operating cash burn has increased across every comparable period: FY2026 used $12.3 million vs $8.3 million in FY2025 (+48%) (10-K FY2026, Consolidated Statements of Cash Flows); Q1 FY2027 used $3.5 million vs $2.6 million in Q1 FY2026 (+35%) (10-Q Q1 FY2027, Condensed Statements of Cash Flows); nine-month FY2026 used $9.4 million vs $5.7 million in nine-month FY2025 (+65%) (10-Q Q3 FY2026, Consolidated Statements of Cash Flows). Financing inflows have been volatile: FY2026 brought $10.2 million, FY2025 brought $8.8 million, nine-month FY2026 brought $10.2 million, but Q1 FY2027 brought $0 (same sources). The net result is a declining cash balance: $9.1 million → $7.0 million → $3.5 million over the three measurement dates (10-K FY2025, 10-K FY2026, 10-Q Q1 FY2027, Consolidated Balance Sheets).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Liquidity metrics have weakened consistently: cash fell from $9.1 million (Mar 2025) to $7.0 million (Mar 2026) to $3.5 million (Jun 2026) (10-K FY2025, 10-K FY2026, 10-Q Q1 FY2027, Consolidated Balance Sheets). Working capital declined from $7.9 million (Mar 2025: $9.6M current assets - $1.7M current liabilities) to $5.9 million (Mar 2026) to $3.1 million (Jun 2026) (same sources). Total assets contracted from $9.8 million to $7.6 million to $4.0 million (same sources). The accumulated deficit expanded from $50.4 million to $67.1 million to $69.8 million (same sources). Current liabilities fell from $1.7 million to $0.8 million, but this was driven by paying down payables and accrued expenses rather than improved fundamentals (10-K FY2026, 10-Q Q1 FY2027, Consolidated Balance Sheets). No debt remains after convertible note conversions completed in March 2025 (10-K FY2026, Note 2).

6. Data Gaps

• Standalone Q2 FY2026 (quarter ended September 30, 2025) and Q4 FY2026 (quarter ended March 31, 2026) income statements and cash flow statements (only nine-month and full-year aggregates provided)
• FY2024 annual financial statements for longer trend analysis
• Detailed investing cash flows for Q1 FY2027 (only operating and financing sections shown in 10-Q Q1 FY2027)
• Revenue breakdown by product/indication (none reported, but confirmation of zero revenue across all segments)
• Capital expenditure forecasts beyond "computer hardware and software" purchases